Skip to main content
SpringerLink
Log in

Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

There is evidence that Chlamydia pneumoniae (CP) is involved in the aetiology of myocardial infarction (MI). Randomised trials do not support a beneficial effect of antibiotics in secondary prevention of MI, but the evidence for an effect on primary prevention is conflicting. We investigated if past use of antibiotics active against CP is associated with a decreased risk of developing MI.

Methods

We conducted a population-based case-control study of 4166 patients hospitalised due to MI from 1 January 1994 to 1 September 1999 in the County of Funen, Denmark. Controls (n=16,664) were a random sample of inhabitants, matched for age and sex. Confounders controlled for in the analysis were gender, age, obstructive pulmonary disease, diabetes, previous MI and known atherosclerotic antecedents. Previous use of antibiotics active against CP (macrolides, tetracyclines and quinolones) and of antibiotics not active against CP (penicillins) was analysed among the cases and controls.

Results

The risk of MI was not associated with previous exposure to macrolides (OR: 1.0; CI: 0.9–1.1), tetracyclines (OR: 1.0; CI: 0.9–1.2) or quinolones (OR: 1.0; CI: 0.9–1.2) or combinations of the three drugs (OR: 1.0; CI: 0.9–1.1). There was no sign of a protective effect in subgroups defined by high cumulative doses of antibiotics, various time-windows of exposure, risk factors of MI or other co-morbidity. OR was 1.1 (0.9–1.3) in persons with no atherosclerotic antecedents.

Conclusion

The study does not support the hypothesis of a decreased risk of MI in patients exposed to antibiotics active against CP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Leinonen M, Saikku P (2002) Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2:11–17

    Article  PubMed  Google Scholar 

  2. Lindholt JS, Fasting H, Henneberg EW, Ostergaard L (1999) A review of Chlamydia pneumoniae and atherosclerosis. Eur J Vasc Endovasc Surg 17:283–289

    Article  PubMed  CAS  Google Scholar 

  3. Ngeh J, Anand V, Gupta S (2002) Chlamydia pneumoniae and atherosclerosis – what we know and what we don't. Clin Microbiol Infect 8:2–13

    Article  PubMed  CAS  Google Scholar 

  4. Dugan JP, Feuge RR, Burgess DS (2002) Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease. Clin Ther 24:719–735

    Article  PubMed  Google Scholar 

  5. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404–407

    PubMed  CAS  Google Scholar 

  6. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B (1999) Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 20:121–127

    Article  PubMed  CAS  Google Scholar 

  7. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR et al (2000) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102:1755–1760

    PubMed  CAS  Google Scholar 

  8. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C et al (1999) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99:1540–1547

    PubMed  CAS  Google Scholar 

  9. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S et al (2003) Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361:809–813

    Article  PubMed  CAS  Google Scholar 

  10. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S et al. (2003) Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290:1459–1466

    Article  PubMed  Google Scholar 

  11. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M et al. (2001) Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 84 (Suppl 3):S669–S675

    PubMed  Google Scholar 

  12. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J et al. (2002) Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 105:1555–1560

    Article  PubMed  CAS  Google Scholar 

  13. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J et al. (2002) Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106:1219–1223

    Article  PubMed  CAS  Google Scholar 

  14. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M et al. (2003) Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 107:1253–1259

    Article  PubMed  Google Scholar 

  15. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C et al (2001) Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357:2085–2089

    Article  PubMed  CAS  Google Scholar 

  16. Etminan M, Carleton B, Delaney JA, Padwal R (2004) Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 24:338–343

    Article  PubMed  CAS  Google Scholar 

  17. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H (1999) Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281:427–431

    Article  PubMed  CAS  Google Scholar 

  18. Muhlestein JB (2003) Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 14:605–614

    Article  PubMed  CAS  Google Scholar 

  19. Gelfand EV, Cannon CP (2004) Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J 147:202–209

    Article  PubMed  CAS  Google Scholar 

  20. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM (2000) Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 181[Suppl 3]:S563–S565

    Article  PubMed  CAS  Google Scholar 

  21. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM (1999) Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 5:281–284

    Article  PubMed  CAS  Google Scholar 

  22. Luchsinger JA, Pablos-Mendez A, Knirsch C, Rabinowitz D, Shea S (2002) Relation of antibiotic use to risk of myocardial infarction in the general population. Am J Cardiol 89:18–21

    Article  PubMed  CAS  Google Scholar 

  23. Herings RM, Leufkens HG, Vandenbroucke JP (2000) Acute myocardial infarction and prior antibiotic use. JAMA 284:2998–2999

    Article  PubMed  CAS  Google Scholar 

  24. Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445–448

    PubMed  CAS  Google Scholar 

  25. Danish Medicines Agency (2004) Drug statistics 1994–1999. Copenhagen, Denmark

  26. Anonymous (1993) Guidelines for ATC classification. In: Rønning M, Sakshaug S (eds) WHO Collaborating Centre for Drug Statistics Methodology, Oslo

  27. WHO Collaborating Centre for Drug Statistics Methodology (1999) ATC index with DDDs annually. WHO, Geneva, Switzerland

  28. Stata Press (1999) STATA for Windows. Stata Statistical Software, Texas

  29. Nielsen HW, Tuchsen F, Jensen MV (1996) Validity of the diagnosis “essential hypertension” in the National Patient Registry. Ugeskr Laeger 158:163–167

    PubMed  CAS  Google Scholar 

  30. Madsen M, Balling H, Eriksen LS (1990) The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry. Ugeskr Laeger 152:308–314

    PubMed  CAS  Google Scholar 

  31. Rothman K, Greenland S (1998) Precision and validity in epidemiological studies. In: Rothman K, Greenland S (eds) Modern epidemiology. Lippincott-Raven, Philadelphia, pp 128–129

    Google Scholar 

  32. Wedzicha JA, Donaldson GC (2003) Exacerbations of chronic obstructive pulmonary disease. Respir Care 48:1204–1213

    PubMed  Google Scholar 

  33. Welin CL, Rosengren A, Wilhelmsen LW (19896) Social relationships and myocardial infarction: a case-control study. J Cardiovasc Risk 3:183–190

    Article  PubMed  CAS  Google Scholar 

  34. Hallqvist J, Lundberg M, Diderichsen F, Ahlbom A (1998) Socioeconomic differences in risk of myocardial infarction 1971–1994 in Sweden: time trends, relative risks and population attributable risks. Int J Epidemiol 27:410–415

    Article  PubMed  CAS  Google Scholar 

  35. Bruinsma N, Hutchinson JM, van den Bogaard AE, Giamarellou H, Degener J, Stobberingh EE (2003) Influence of population density on antibiotic resistance. J Antimicrob Chemother 51:385–390

    Article  PubMed  CAS  Google Scholar 

  36. Ostergaard L, Sorensen HT, Lindholt J, Sorensen TE, Pedersen L, Eriksen T et al (2001) Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: a comparative prospective cohort study. J Infect Dis 183:1625–1630

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study was funded by The Danish Health foundation.

Author information

Authors and Affiliations

  1. Research Unit of General Practice, University of Southern Denmark, J.B. Winslows Vej 9, 5000, Odense C, Denmark

    Lars Bjerrum & Morten Andersen

  2. Department of Clinical Pharmacology, University of Southern Denmark, Odense, Denmark

    Morten Andersen & Jesper Hallas

Authors
  1. Lars Bjerrum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morten Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jesper Hallas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Bjerrum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bjerrum, L., Andersen, M. & Hallas, J. Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction. Eur J Clin Pharmacol 62, 43–49 (2006). https://doi.org/10.1007/s00228-005-0059-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0059-x

Keywords

Search

Navigation